Clinical Trial: NCT05654623
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 3| Lead Sponsor: | Pfizer |
| Information Provided By: | Pfizer |
| Last Update Posted: | 2026-03-18 |
Study Overview
Brief Summary
A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.
Official Title
A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER TRIAL OF ARV-471 (PF-07850327) VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE (VERITAC-2)
Conditions
Advanced Breast Cancer
Intervention / Treatment
- Drug: ARV-471
- Drug: Fulvestrant
Other Study ID Numbers
- C4891001
- 2022-500544-38-00
Start Date (Actual)
2023-03-03
Primary Completion Date (Actual)
2025-01-31
Study Completion Date (Estimated)
2028-05-15
Enrollment (Actual)
624
Study Type
Interventional
Phase
Phase 3
| Lead Sponsor: | Pfizer |
| Information Provided By: | Pfizer |
| Last Update Posted: | 2026-03-18 |
Study Overview
Brief Summary
A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.
Official Title
A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER TRIAL OF ARV-471 (PF-07850327) VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE (VERITAC-2)
Conditions
Advanced Breast Cancer
Intervention / Treatment
- Drug: ARV-471
- Drug: Fulvestrant
Other Study ID Numbers
- C4891001
- 2022-500544-38-00
Start Date (Actual)
2023-03-03
Primary Completion Date (Actual)
2025-01-31
Study Completion Date (Estimated)
2028-05-15
Enrollment (Actual)
624
Study Type
Interventional
Phase
Phase 3